Shares of Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biopharmaceutical company, are surging in response to positive clinical results from a stomach cancer study. Last September, Leap Therapeutics stock more than doubled overnight after the company reported impressive response rate data for its lead candidate DKN-1 plus tislelizumab from BeiGene (NASDAQ: BGNE). The experimental combination treatment was tested among patients newly diagnosed with advanced-stage stomach cancer.